Patients with first-episode psychosis generally respond well to antipsychotic medication, often at lower doses than chronic patients, and rates of remission are high. However, first-episode patients are also more sensitive to many adverse effects of antipsychotic medication including weight gain, hyperprolactinaemia and extrapyramidal symptoms (Haddad et al., 2011; Haddad and Sharma, 2007) . Sexual dysfunction and weight gain may be particularly distressing to young people. Adverse effects early in treatment may shape long-term views about medication and have a detrimental influence on medication adherence. The choice of medication should be made jointly by the patient and their psychiatrist. Antipsychotics differ markedly in their adverse effect profiles but their efficacy is similar in schizophrenia, with the exception of clozapine which has superior efficacy in treatmentresistant schizophrenia. Consequently the patient's views about potential adverse effects are likely to have a major influence on choice of medication. Antipsychotics should be commenced at a relatively low dose due to the sensitivity of first-episode patients to both therapeutic and adverse effects. Systematic screening for adverse effects is important in all patients but especially within this group.
Rates of medication non-adherence are high in EI patients, with one study finding that approximately 60% of patients had adherence problems during their first year of treatment (Coldham et al., 2002) . Non-adherence is a frequent cause of relapse. In a 5-year observational study of patients with firstepisode psychosis, the rate of relapse was nearly fivefold higher among those who stopped antipsychotic medication compared with those who continued treatment (Robinson et al., 1999 ). An important way to improve adherence is for the clinician to gain a better understanding of the patient's beliefs about their illness, the role of medication and any barriers to medication taking. The clinician can then work with the patient to help them understand how medication may help on an individual level. This process should also allow the patient and prescriber to make a joint decision on the choice of medication, so that the balance between the potential advantages and disadvantages of medication is more attractive to the patient.
Rates of substance misuse, particularly of alcohol and cannabis, are high in patients seen in EI services (Barnes et al., 2006) . Despite initial controversy there is strong evidence that cannabis use, particularly at a young age, is an independent risk factor for the development of psychosis (Semple et al., 2005) . Substance misuse is associated with an increased DUP (Thomas and Nandhra, 2009). This may partly reflect a patient perceiving their initial psychotic symptoms as drug induced, rather than representing a psychiatric illness, leading them to delay obtaining medical help. Even when substance misuse is not a causal factor in the original development of psychosis, it may precipitate a relapse. Substance use is associated with poor medication adherence (Coldham et al., 2002) and can lead to physical and social problems in its own right. Not surprisingly, persistent substance misuse is associated with a range of poorer outcomes at 1 year in first-episode patients, including poorer functional response, a higher relapse rate and a greater symptom burden (Turkington et al., 2009) .
Several trials have suggested that both antipsychotics and cognitive therapy can prevent or delay the onset of psychosis in 'high-risk' non-psychotic individuals (McGorry et al., 2002; Morrison et al., 2004) . Deciding how to apply these findings in clinical practice raises ethical and practical dilemmas and is controversial. The supporting studies are small, there are no data on long-term outcomes and only a minority of high-risk individuals develop psychosis, but currently it is impossible to identify this subset. Consequently one may treat many patients unnecessarily, possibly with antipsychotic drugs which can cause significant adverse effects. At present no firm guidance can be offered on treatment approaches for potential prodromal patients and cases must be dealt with on an individual patient basis, with the patient making a fully informed decision about treatment.
Working with EI patients has many challenges but is extremely rewarding. Compared with multi-episode patients, the psychotic illness tends to be more responsive to treatment and many secondary disabilities have not yet accrued. There is the hope that effective intervention at this critical time may improve the long-term prognosis. Many EI patients receive extensive support from relatives, and family interventions can reduce the risk of relapse. Early intervention is an area of active research and it is hoped that this should eventually lead to better treatments and improved outcomes.
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